WO2020202128A1 - Herbal gel composition and its process of preparation - Google Patents

Herbal gel composition and its process of preparation Download PDF

Info

Publication number
WO2020202128A1
WO2020202128A1 PCT/IB2020/054662 IB2020054662W WO2020202128A1 WO 2020202128 A1 WO2020202128 A1 WO 2020202128A1 IB 2020054662 W IB2020054662 W IB 2020054662W WO 2020202128 A1 WO2020202128 A1 WO 2020202128A1
Authority
WO
WIPO (PCT)
Prior art keywords
gel composition
agent
topical
propylene glycol
penetration enhancer
Prior art date
Application number
PCT/IB2020/054662
Other languages
French (fr)
Inventor
Shrinivasan SHESHA IYENGAR
Hemanth Kumar BOTHRA
Original Assignee
Lyrus Life Sciences Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lyrus Life Sciences Pvt Ltd filed Critical Lyrus Life Sciences Pvt Ltd
Publication of WO2020202128A1 publication Critical patent/WO2020202128A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/32Burseraceae (Frankincense family)
    • A61K36/324Boswellia, e.g. frankincense
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/74Rubiaceae (Madder family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Definitions

  • the present invention relates to topical herbal composition
  • topical herbal composition comprising natural herbal extracts as active ingredients and pharmaceutically acceptable excipients or carriers.
  • the present invention also relates to topical herbal gel composition
  • topical herbal gel composition comprising boswellia extract, green coffee bean extract as natural herbal extracts, optionally capsaicin as additional active ingredient and pharmaceutically acceptable excipients or carriers.
  • the present invention also relates to topical herbal gel composition
  • topical herbal gel composition comprising boswellia extract, green coffee bean extract as natural herbal extracts, optionally capsaicin as additional active ingredient and phospholipid as skin penetration enhancer and other pharmaceutically acceptable excipients or carriers for relief of pain in arthritis condition or for relief of musculoskeletal pain.
  • the present invention also relates to process for the preparation of topical herbal gel composition comprising steps of dissolving, mixing, sonicating and packing.
  • Arthritis is a long-term autoimmune disorder that primarily affects joints.
  • a common feature of rheumatic diseases is the involvement of joints and the surrounding tissues such as ligaments, tendons and muscles which results swollen and painful joints. Pain and stiffness often worsen following rest and most commonly, the wrist and hands are involved, with the same joints typically involved on both sides of the body.
  • Arthritis is generally considered to be due to degradation by extended use of the joints leading to damage of the joint surfaces, which results in pain on movement of the joint, so that the greatest pain is experienced.
  • Boswellia serrata is a medium to large branching tree, generally found in dry hilly areas of India, North Africa, and the Middle East, belongs to the family Burseraceae. Boswellia serrata is called Indian olibanum, Indian frankincense or “Dhup”, it is also known as Salai guggul, and Sallaki in Sanskrit.
  • Boswellia serrata in Sanskrit is known as Gajabhakshya, implying its ingestion by elephants. Charaka, Bhavamisra and others have described it as useful. It possesses anti-inflammatory, anti-arthritic and analgesic activity.
  • Boswellia serrata plant contains boswellic acid as its major active constituent which is present as a- boswellic acid; b- boswellic acid; 3 - acetyl- 11-keto b -boswellic acid (AKBA), responsible for anti-arthritic activity. From ancient times Boswellia serrata is being used in the management of rheumatoid arthritis, osteoarthritis solely because of these potent active constituents.
  • Boswellic acid shows its activity by inhibiting the synthesis of pro-inflammatory cytokines and 5-lipoxygenase activity.
  • the resin extracted from plant has many pharmacological uses.
  • the oleo-gum resin of Boswellia Serrata is a complex mixture of lower and higher Terpenoids and carbohydrates. Higher Terpenoids, collectively called the Boswellic acids are the major fraction of the resin (25-35%), Boswellic acid 65%-85%.
  • the boswellic acid is shown below:
  • Boswellia serrata contains, monoterpenes (a-thujene); diterpenes (macrocyclicditerpenoids such as incensole, incensole oxide, iso-incensole oxide, a diterpene alcohol [serratol]); triterpenes (such as a- and B-amyrins); pentacyclictriterpenic acids (boswellic acids); tetracyclic triterpenic acids (tirucall-8, 24-dien-21-oic acids) used in the treatment of rheumatism, arthritis, relives pain, dysentery, dyspepsia, lung diseases, haemorrhoids, lowers cholesterol, boosts Immunity, relieve asthma urinary disorders, corneal ulcer in unani System, anti-cancer activity, anti-diabetic activity, neuroprotective effects.
  • monoterpenes a-thujene
  • diterpenes microcyclicditerpenoids such as inc
  • the gum resins of Boswellia serrata has been used for a variety of therapeutic purposes such as inflammation, arthritis, analgesia, pain, cancer, asthma, colitis, Crohn’s diseases and hyperlipidemia.
  • Coffee plants belong to the botanical family Rubiaceae, which includes approximately 80 species. Green coffee beans are seeds of the fruit (coffee cherry) of the coffee tree, which is oval and approximately 10 mm in size. Green coffee beans surrounded by a thin seed skin known as coffee silverskin, an endocarp layer known as the parchment, a pectic adhesive layer, pulp, and an epicarp (outer skin).
  • Green coffee beans are simply beans that have not been roasted and in the purest and rawest form. These raw beans are used to make the green coffee extract. The trees themselves resemble a tall bush, and the coffee beans they produce are in fact the seeds, which known as the coffee 'cherry' fruit.
  • Green coffee beans are generally produced by purification and thresh processes, which completely remove the outer skin, pulp, pectic adhesive layer, and parchment from the green coffee beans. The remaining part of the green coffee beans are then roasted using dry heat at temperatures between 200° and 300°C with constant agitation to ensure even heating. During roasting, the colour of green coffee beans changes to yellow, then to a suntan-like light brown, and later to a dark, oily brown colour.
  • Chlorogenic acid was isolated from green coffee beans. It has also been found in the seeds and leaves of many dicotyledonous plants. It is thermally unstable and is readily decomposed to quinic acid and caffeic acid. Chlorogenic acid accounts for 5- 10% of coffee beans, which is a much larger amount than caffeine (1-2%). It forms greenish-black compounds in the presence of Fe(III) ion. Due to its radical-capturing ability, an antioxidant activity is expected.
  • Chlorogenic acid is a phytochemical found in coffee and coffee beans. Chlorogenic acid is a cinnamate ester obtained by formal condensation of the carboxy group of trans-caffeic acid with the 3 -hydroxy group of quinic acid. It is an intermediate metabolite in the biosynthesis of lignin.
  • Capsaicin is chemically, 8-methyl-N-vanillyl-6-nonenamide is an active component of chilli peppers, belonging to the genus Capsicum. Capsaicin and several related compounds are called capsaicinoids and are produced as secondary metabolites by chilli peppers, probably as deterrents against certain mammals and fungi. Pure capsaicin is a hydrophobic, colorless, highly pungent, and crystalline to waxy solid compound. This compound was first extracted in impure form in 1816 by Christian Friedrich Bucholz.
  • Capsaicin (trans-8-methyl-N-vanillyl-6-nonenamide) is an active component. Although there are two geometric isomers of capsaicin, only trans-capsaicin occurs naturally. Capsaicin structural formula is as follows:
  • Capsaicin is responsible for the hot sensation in the mucous membranes when eating chili peppers. It works by attaching to the nerve receptor known as the transient receptor potential vanillod 1 (TRPV1), which activates cation channels on C nerve fibers and some A delta nerve fibers resulting in neuronal calcium influx and a sudden release of the chemical mediator in sensory nerves called substance P.
  • TRPV1 transient receptor potential vanillod 1
  • Boswellia serrata substantially contains the following ingredients: b-boswellic acid, acetyl-P-boswellic acid, acetyl- l l-keto-P-boswellic acid, l l-keto-P-boswellic acid and small portions of a- and b-boswellic acid and the tirucallic acids.
  • the U.S. patent No. 5,888,514 A refers to a composition for treating a mammal having a condition characterized by bone or joint inflammation where extract of Boswellia serrata is used as one of the ingredients among the other inflammatory agents.
  • the EP Publication No. 0 552 657 A1 disclose that pure boswellic acid, physiologically acceptable salts thereof, derivatives thereof and salts of the derivatives or a boswellic acid-containing vegetable preparation may combat inflammatory processes caused by an increased leukotriene formation. Therefore, said publications propose that the compounds be used in particular for treating inflammatory arthropathies, epidermal lesions, allergic and chronic asthma, endotoxin shock, inflammatory bowel diseases and chronic hepatitis and also discloses the use of boswellic acid for treating the inflammatory processes alone or in combination with the other herbal medicines.
  • the US patent No. 7,282,224 B1 discloses the topical pain relief composition comprising capsaicin, a capsaicinoid, a capsaicin analogue and combinations as pain relieving component and Boswellia as inflammation control component.
  • composition which comprise at least one ingredient chosen from rosehips, blueberry, blackberry, elderberry, cranberry, rosemary, clove, feverfew, nettle root, artichoke, reishi mushroom, olive extract, green tea extract (epigallocatechin gallate), grape seed extract, resveratrol, viniferin, Aframomum melegueta, boswellia serrata extract, boswellia forte, ipriflavone, tocotrienols, evening primrose oil, INM-176, borage oil, krill oil, at least one type of xanthophyll (e.g., astaxanthin), green coffee extract (chlorogenic acid), and ferulic acid.
  • xanthophyll e.g., astaxanthin
  • green coffee extract chlorogenic acid
  • ferulic acid e.g., astaxanthin
  • compositions and methods for making compositions derived from Boswellia species frankincense or olibanum
  • Boswellia species frankincense or olibanum
  • human oral delivery formulations and methods for use of such compositions, useful e.g. for treating/preventing arthritis, inflammatory disorders, osteoarthritis, rheumatoid diseases and low back pain.
  • the US publication No. US 2011/0052738 A1 discloses the Boswellia serrata extract and capsaicin in topical pain composition comprising one or more skin penetrants includes soya lecithin, phosphatidyl choline, propylene glycol, derivatized propylene glycol, diethylene glycol monomethylether, diethylene glycol monoethyl ether, propylene glycol monolaurate, tri-block polyethers, isopropyl myristate, stearic acid, dimethyl sulfoxide, poloxamer 407, and combinations thereof.
  • Jan Husch et ah, Fitorick, 2013, volume 84, pages 89-98 discloses the enhancement of use of lecithin delivery in the Phytosome ® form of Boswellia extract.
  • the US publication No. 2014/0134261 A1 discloses pharmaceutical composition comprising ester of capsaicin or its analogue and other agent selected from salicylate, menthol, a boswellic acid, DMSO, methyl sulfonylmethane, an NSAID, a corticosteroid, emu oil, an opioid agonist, an opiod antagonist, an NMDA antagonist, tramadol, an a2d ligand, santalol, santalyl acetate, amyris alcohol, amyris acetate, aloe vera gel and aloe vera juice.
  • other agent selected from salicylate, menthol, a boswellic acid, DMSO, methyl sulfonylmethane, an NSAID, a corticosteroid, emu oil, an opioid agonist, an opiod antagonist, an NMDA antagonist, tramadol, an a2d
  • the PCT publication No. WO 2018/020512 A1 discloses the composition for slow/sustained/controlled release of at last one active ingredient wherein the active ingredients are selected from natural phytochemicals, phytochemical is selected from all hydrophobic and hydrophilic natural compounds, but not limited to, Lutein, Caffeine, Resveratrol, Berberin, 95% Curcuminoids, Gingerols, Bacosides, Boswellic Acids, Chlorogenic Acids combinations thereof.
  • Boswellia extract in different compositions and process for the preparations of Boswellia extract.
  • topical gel compositions are not available containing boswellia extract, green coffee bean extract as active ingredients, optionally capsaicin as additional active ingredient and phospholipid as skin penetration enhancer and pharmaceutically acceptable excipients or carriers.
  • the inventors of present invention also provides process for the preparation of topical gel composition comprising steps of dissolving, mixing, sonicating and packing.
  • the main objective of the present invention is to provide topical herbal composition comprising natural herbal extracts as active ingredients and pharmaceutically acceptable excipients or carriers.
  • Another objective of the present invention is to provide topical herbal gel composition
  • boswellia extract and green coffee bean extract as natural herbal extracts, optionally capsaicin as additional active ingredient, phospholipid as skin penetration enhancer and other pharmaceutically acceptable excipients or carriers.
  • Still another objective of the present invention is to provide process for the preparation of topical herbal gel composition comprising steps of dissolving, mixing, sonicating and packing.
  • Yet another objective of the present invention is to provide relief of pain in arthritis conditions or relief of musculoskeletal pain by topical application of herbal gel composition of boswellia extract, green coffee bean extract and optionally capsaicin as additional active ingredient and other pharmaceutically acceptable excipients or carriers.
  • One embodiment of the present invention provides topical composition comprising natural herbal extracts as active ingredients and pharmaceutically acceptable excipients or carriers.
  • Another embodiment of the present invention provides a topical herbal gel composition
  • a topical herbal gel composition comprising boswellia extract, green coffee bean extract as natural herbal extracts and optionally, capsaicin as additional active ingredient and pharmaceutically acceptable excipients or carriers.
  • Another embodiment of the present invention provides a topical herbal gel composition
  • a topical herbal gel composition comprising boswellia extract, green coffee bean extract as natural herbal extracts, and optionally, capsaicin as additional active ingredient, phospholipid as skin penetration enhancer and pharmaceutically acceptable excipients or carriers.
  • Another embodiment of the present invention provides topical herbal gel composition
  • topical herbal gel composition comprising boswellia extract, green coffee bean extract as natural herbal extracts and optionally, capsaicin as additional active ingredient and phospholipid as skin penetration enhancer, solvents, humectants, surfactants, additional penetration enhancer, anti-foaming agents and other pharmaceutically acceptable excipients.
  • Another embodiment of the present invention provides a topical herbal gel composition
  • a topical herbal gel composition comprising boswellia extract, green coffee bean extract as natural herbal extracts and optionally, capsaicin as additional active ingredient and phospholipid as skin penetration enhancer, solvents, humectants, surfactants, additional penetration enhancer, anti-foaming agents and other pharmaceutically acceptable excipients for relief of pain in arthritis condition or for relief of musculoskeletal pain.
  • the present invention provides a topical herbal gel composition comprising:
  • the present invention provides a topical herbal gel composition comprising:
  • the present invention provides a topical herbal gel composition comprising:
  • capsaicin optionally,
  • in yet another embodiment of the present invention is to provide process for the preparation of topical herbal gel composition
  • topical herbal gel composition comprising boswellia extract, green coffee bean extract as natural herbal extracts and optionally, capsaicin as additional active ingredient, phospholipid as skin penetration enhancer, solvents, humectants, surfactants, additional penetration enhancer, anti-foaming agents and other pharmaceutically acceptable excipients comprising steps of dissolving, mixing, sonicating and packing.
  • the present invention was aimed to develop topical herbal gel preparation comprising natural herbal extracts as active ingredients and pharmaceutically acceptable excipients or carriers.
  • the present invention is to provide topical herbal gel composition comprising boswellia extract, green coffee bean extract as natural herbal extracts and optionally capsaicin as additional active ingredient, phospholipid as skin penetration enhancer and pharmaceutically acceptable excipients or carriers.
  • the present invention is to provide topical herbal gel composition comprising boswellia extract, green coffee bean extract as natural herbal extracts and optionally capsaicin as additional active ingredient, phospholipid as skin penetration enhancer and other pharmaceutically acceptable excipients for relief of pain in arthritis condition or for relief of musculoskeletal pain.
  • the present invention is to provide an efficient process for the preparation of topical herbal gel composition comprising the steps of dissolving, mixing, sonicating and packing.
  • active ingredients are used to relieve from pain conditions.
  • active ingredients are boswellia extract, green coffee bean extract and optionally, capsaicin as additional active ingredient.
  • Boswellia serrata plant contains boswellic acid as its major active constituent which is present as a- boswellic acid; b- boswellic acid; 3 - acetyl- 11-keto b -boswellic acid (AKBA), responsible for anti- arthritic activity.
  • AKBA acetyl- 11-keto b -boswellic acid
  • Boswellia serrata possesses monoterpenes, diterpenes, triterpenes, tetracyclic triterpenic acids and four major pentacyclic triterpenic acids i.e. b-boswellic acid, acetyl ⁇ -boswellic acid, l l-keto ⁇ -boswellic acid and acetyl- 11- keto ⁇ -boswellic acid, responsible for inhibition of pro-inflammatory enzymes.
  • acetyl- l l-keto ⁇ -boswellic acid is the most potent inhibitor of 5-lipoxygenase, an enzyme responsible for inflammation.
  • Boswellia serrata has been used for a variety of therapeutic purposes such as cancer, analgesia, asthma, inflammation, arthritis, colitis, Crohn’s diseases and hyperlipidemia.
  • Green coffee bean extract Green (or raw) coffee is a major source of CGA in nature (5-12 g/100 g).
  • Chlorogenic acids (CGA) are cinnamic acid derivatives with biological effects mostly related to their antioxidant and anti-inflammatory activities.
  • Chlorogenic acids (CGA) are phenolic compounds formed by the esterification of cinnamic acids, such as caffeic, ferulic, and p-coumaric acids, with (-)-quinic acid.
  • capsaicin and several related compounds are called capsaicinoids and are produced as secondary metabolites by chili peppers, probably as deterrents against certain mammals and fungi. Pure capsaicin is a hydrophobic, colorless, highly pungent, and crystalline to waxy solid compound.
  • Capsaicin is used as an analgesic in topical ointments and dermal patches to relieve pain, typically in concentrations between 0.025% and 0.1%. It may be applied in cream form for the temporary relief of minor aches and pains of muscles and joints associated with arthritis, backache, strains and sprains, often in compounds with other rubefacients. Capsaicin exhibits anti-inflammatory property by inhibiting IkB-a degradation in LPS- stimulated peritoneal macrophages and it has both analgesic and anti-inflammatory properties.
  • Capsaicin transdermal patch for the management of this particular therapeutic indication (pain due to post-herpetic neuralgia) was approved as a therapeutic by the U.S. FDA.
  • One of clinical studies having limited quality found that high-dose topical capsaicin (8%) compared with control (0.4% capsaicin) provided moderate to substantial pain relief from post herpetic neuralgia, HIV-neuropathy, and diabetic neuropathy.
  • Phosphatidylcholines are a class of phospholipids that incorporate choline as a head group. They are a major component of biological membranes and can be easily obtained from a variety of readily available sources, such as egg yolk or soybeans, from which they are mechanically or chemically extracted using hexane.
  • Phosphatidylcholine is a chemical contained in eggs, soybeans, mustard, sunflower, and other foods. It is found naturally in the body in all cells.
  • phosphatidylcholine is sometimes used interchangeably with “lecithin,” although the two are different.
  • Phosphatidylcholine is a major constituent of cell membranes and pulmonary surfactant, and is more commonly found in the exoplasmic or outer leaflet of a cell membrane. It is thought to be transported between membranes within the cell by phosphatidylcholine transfer protein (PCTP). Phosphatidylcholine also plays a role in membrane-mediated cell signaling and PCTP activation of other enzymes.
  • PCTP phosphatidylcholine transfer protein
  • One or more skin penetration enhancers selected from the group consisting of soya lecithin, phosphatidyl choline, propylene glycol, derivatized propylene glycol, diethylene glycol monomethylether, diethylene glycol monoethyl ether, propylene glycol monolaurate, tri-block polyethers, isopropyl myristate, stearic acid, dimethyl sulfoxide, poloxamer 407, and combinations thereof.
  • skin penetration enhancer is phosphatidyl choline and
  • isopropyl myristate is additional skin penetration enhancer.
  • Penetration enhancer used in the herbal gel composition is in the range of 0.1 to 10 %(w/w), more preferably in the range of 1% to 5% (w/w) of the total weight of the composition.
  • Additional penetration enhancer used in the herbal gel composition is in the range of 1% to 10 % (w/w) of additional penetration enhancer, more preferably in the range of 1% to 5% (w/w) of the total weight of the composition.
  • the solvent is selected from a group comprising ethyl alcohol, isopropyl alcohol, glycofurol, polyethylene glycol (PEG 200, 400), glycerol, polypropylene glycol, propylene glycol, N-methyl-2-pyrolidone and ethyl alcohol or mixture thereof.
  • the solvent is ethyl alcohol.
  • Solvent used in the herbal gel composition is in the range of 0.5% to 20% (w/w), more preferably in the range of 5% to 15% (w/w) of the total weight of the composition.
  • the preferred surfactant referred above can be polyglutamic acid, Polyethylene glycol, propylene glycol, glycerol, propylene glycol esters, polyglycerol oleate polyvinyl alcohol, non-ethoxylated polymers like Glyceryl Stearate (and) Polyglyceryl-6 Palmitate/Succinate (and) Cetearyl Alcohol and N-(2- Hydroxypropyl) methacrylamide (PHPMA).
  • Preferred polyethylene glycols having a molecular weight range from about 300 to about 1500. More preferred are the polyethylene glycols having a molecular weight range from about 600 to about 1500. Most preferred are the polyethylene glycols having a high molecular weight range from about 1500.
  • Surfactant used in the herbal gel composition is in the range of 10% to 70% (w/w), more preferably in the range of 30% to 64.5% (w/w) of the total weight of the composition.
  • Humectants include but are not limited to glycerine, sorbitol, propylene glycol, Butylene Glycol, Aluminum Hydroxide Adjuvant, Ammonium Alginate, Cyclomethicone, Polydextrose, Sodium Hyaluronate, Sodium Lactate, Triacetin, Triethanolamine and Xylitol.
  • the humectant is glycerine.
  • Humectants used in the herbal gel composition is in the range of 1% to 15% (w/w), more preferably in the range of 5% to 10% (w/w) of the total weight of the composition.
  • Anti-foam agents and defoamer are often used interchangeably and commonly used in the compositions of the present invention are Simethicone, polydimethylsiloxanes and other silicones, certain alcohols, stearates and glycols, Alkyl poly acrylates, Castor oil, Fatty acids, Fatty acids esters, Fatty acids sulfate, Fatty alcohol, Fatty alcohol esters, Fatty alcohol sulfate, Foot olive oil, Mono & Di Glyceride, Paraffin oil, Paraffin Wax, Poly Propylene Glycol, Silicones Oil, Vegetable & animal fats. More preferably Simethicone is used.
  • Anti-foam agent and defoamer used in the herbal gel composition is in the range of 0.01 to 0.1% (w/w), more preferably in the range of 0.05 to 0.1% (w/w) of the total weight of the composition.
  • excipients or carriers used in the preparations to the compositions of this invention can be used and there were no limitations: stabilizer, plasticizer, lubricant, reducing agent, buffer agent, base, adsorbent, corrigent, binder, suspending agent, antioxidant, wetting agent, wet modifier, filler, refrigerative agent, coloring matter, flavoring agent, perfume, isotonizing agent, softener, emulsifying agent, foaming agent, pH modifier, anti-frothing agents, flavouring agents, preservatives, dispersing agent, fragrance, desiccant, antiseptics, preservative, solubilizing agent, solubilizer, solvent, superplasticizer, antistatic agent, extender, moisturizing agent and the like.
  • Manufacturing process for topical herbal gel composition a. adding the natural herbal extracts, optionally additional active ingredient and phospholipid as skin penetration enhancer, additional penetration enhancer, surfactant, solvent, humectant, and anti-foaming agent, b. mixing the above mixture by sonication process using Hiescher Ultra sound sonicator for ninety seconds at a time and resting for thirty seconds alternatively till a total power of 50,000 watts energy is used to obtain clear gel preparation.
  • Manufacturing process a. adding the boswellia extract, green coffee bean extract and optionally capsaicin as additional active ingredient and phosphotidyl choline and polyethylene glycol 1500, glycerine, ethyl alcohol, isopropyl myristate and simethicone, b. mixing the above mixture by sonication process using Hiescher Ultra sound sonicator for ninety seconds at a time and resting for thirty seconds alternatively till a total power of 50,000 watts energy is used to obtain clear gel preparation.

Abstract

The present invention relates to topical herbal composition comprising natural herbal extracts as active ingredients and pharmaceutically acceptable excipients or carriers. The present invention also relates to topical herbal gel composition comprising boswellia extract, green coffee bean extract as natural herbal extracts, optionally capsaicin as additional active ingredient and pharmaceutically acceptable excipients or carriers. The present invention also relates to topical herbal gel composition comprising boswellia extract, green coffee bean extract as natural herbal extracts, optionally capsaicin as additional active ingredient and phospholipid as skin penetration enhancer and other pharmaceutically acceptable excipients or carriers for relief of pain in arthritis condition or for relief of musculoskeletal pain. The present invention also relates to process for the preparation of topical herbal gel composition comprising steps of dissolving, mixing, sonicating and packing.

Description

HERBAL GEL COMPOSITION AND ITS PROCESS OF
PREPARATION
FIELD OF THE INVENTION
The present invention relates to topical herbal composition comprising natural herbal extracts as active ingredients and pharmaceutically acceptable excipients or carriers.
The present invention also relates to topical herbal gel composition comprising boswellia extract, green coffee bean extract as natural herbal extracts, optionally capsaicin as additional active ingredient and pharmaceutically acceptable excipients or carriers.
The present invention also relates to topical herbal gel composition comprising boswellia extract, green coffee bean extract as natural herbal extracts, optionally capsaicin as additional active ingredient and phospholipid as skin penetration enhancer and other pharmaceutically acceptable excipients or carriers for relief of pain in arthritis condition or for relief of musculoskeletal pain.
The present invention also relates to process for the preparation of topical herbal gel composition comprising steps of dissolving, mixing, sonicating and packing.
BACKGROUND OF THE INVENTION
Arthritis is a long-term autoimmune disorder that primarily affects joints. A common feature of rheumatic diseases is the involvement of joints and the surrounding tissues such as ligaments, tendons and muscles which results swollen and painful joints. Pain and stiffness often worsen following rest and most commonly, the wrist and hands are involved, with the same joints typically involved on both sides of the body. Arthritis is generally considered to be due to degradation by extended use of the joints leading to damage of the joint surfaces, which results in pain on movement of the joint, so that the greatest pain is experienced. Boswellia serrata
Boswellia serrata is a medium to large branching tree, generally found in dry hilly areas of India, North Africa, and the Middle East, belongs to the family Burseraceae. Boswellia serrata is called Indian olibanum, Indian frankincense or “Dhup”, it is also known as Salai guggul, and Sallaki in Sanskrit.
Boswellia serrata, in Sanskrit is known as Gajabhakshya, implying its ingestion by elephants. Charaka, Bhavamisra and others have described it as useful. It possesses anti-inflammatory, anti-arthritic and analgesic activity. Boswellia serrata plant contains boswellic acid as its major active constituent which is present as a- boswellic acid; b- boswellic acid; 3 - acetyl- 11-keto b -boswellic acid (AKBA), responsible for anti-arthritic activity. From ancient times Boswellia serrata is being used in the management of rheumatoid arthritis, osteoarthritis solely because of these potent active constituents. Boswellic acid shows its activity by inhibiting the synthesis of pro-inflammatory cytokines and 5-lipoxygenase activity.
The resin extracted from plant has many pharmacological uses. The oleo-gum resin of Boswellia Serrata is a complex mixture of lower and higher Terpenoids and carbohydrates. Higher Terpenoids, collectively called the Boswellic acids are the major fraction of the resin (25-35%), Boswellic acid 65%-85%. The boswellic acid is shown below:
Figure imgf000004_0001
b-Boswellic acid
The resinous part of Boswellia serrata contains, monoterpenes (a-thujene); diterpenes (macrocyclicditerpenoids such as incensole, incensole oxide, iso-incensole oxide, a diterpene alcohol [serratol]); triterpenes (such as a- and B-amyrins); pentacyclictriterpenic acids (boswellic acids); tetracyclic triterpenic acids (tirucall-8, 24-dien-21-oic acids) used in the treatment of rheumatism, arthritis, relives pain, dysentery, dyspepsia, lung diseases, haemorrhoids, lowers cholesterol, boosts Immunity, relieve asthma urinary disorders, corneal ulcer in unani System, anti-cancer activity, anti-diabetic activity, neuroprotective effects.
The gum resins of Boswellia serrata has been used for a variety of therapeutic purposes such as inflammation, arthritis, analgesia, pain, cancer, asthma, colitis, Crohn’s diseases and hyperlipidemia.
Green coffee bean extract
Coffee plants belong to the botanical family Rubiaceae, which includes approximately 80 species. Green coffee beans are seeds of the fruit (coffee cherry) of the coffee tree, which is oval and approximately 10 mm in size. Green coffee beans surrounded by a thin seed skin known as coffee silverskin, an endocarp layer known as the parchment, a pectic adhesive layer, pulp, and an epicarp (outer skin).
Green coffee beans are simply beans that have not been roasted and in the purest and rawest form. These raw beans are used to make the green coffee extract. The trees themselves resemble a tall bush, and the coffee beans they produce are in fact the seeds, which known as the coffee 'cherry' fruit.
Green coffee beans are generally produced by purification and thresh processes, which completely remove the outer skin, pulp, pectic adhesive layer, and parchment from the green coffee beans. The remaining part of the green coffee beans are then roasted using dry heat at temperatures between 200° and 300°C with constant agitation to ensure even heating. During roasting, the colour of green coffee beans changes to yellow, then to a suntan-like light brown, and later to a dark, oily brown colour.
Chlorogenic acid was isolated from green coffee beans. It has also been found in the seeds and leaves of many dicotyledonous plants. It is thermally unstable and is readily decomposed to quinic acid and caffeic acid. Chlorogenic acid accounts for 5- 10% of coffee beans, which is a much larger amount than caffeine (1-2%). It forms greenish-black compounds in the presence of Fe(III) ion. Due to its radical-capturing ability, an antioxidant activity is expected.
Chlorogenic acid is a phytochemical found in coffee and coffee beans. Chlorogenic acid is a cinnamate ester obtained by formal condensation of the carboxy group of trans-caffeic acid with the 3 -hydroxy group of quinic acid. It is an intermediate metabolite in the biosynthesis of lignin.
Figure imgf000005_0001
Capsaicin Capsaicin is chemically, 8-methyl-N-vanillyl-6-nonenamide is an active component of chilli peppers, belonging to the genus Capsicum. Capsaicin and several related compounds are called capsaicinoids and are produced as secondary metabolites by chilli peppers, probably as deterrents against certain mammals and fungi. Pure capsaicin is a hydrophobic, colorless, highly pungent, and crystalline to waxy solid compound. This compound was first extracted in impure form in 1816 by Christian Friedrich Bucholz.
Capsaicin (trans-8-methyl-N-vanillyl-6-nonenamide) is an active component. Although there are two geometric isomers of capsaicin, only trans-capsaicin occurs naturally. Capsaicin structural formula is as follows:
Figure imgf000006_0001
Capsaicin is responsible for the hot sensation in the mucous membranes when eating chili peppers. It works by attaching to the nerve receptor known as the transient receptor potential vanillod 1 (TRPV1), which activates cation channels on C nerve fibers and some A delta nerve fibers resulting in neuronal calcium influx and a sudden release of the chemical mediator in sensory nerves called substance P.
Pardhy & Bhattacharyya reported in Ind. J. Chem., 16 b: 1978, pp 176-178, that Boswellia serrata substantially contains the following ingredients: b-boswellic acid, acetyl-P-boswellic acid, acetyl- l l-keto-P-boswellic acid, l l-keto-P-boswellic acid and small portions of a- and b-boswellic acid and the tirucallic acids.
The U.S. patent No. 5,888,514 A refers to a composition for treating a mammal having a condition characterized by bone or joint inflammation where extract of Boswellia serrata is used as one of the ingredients among the other inflammatory agents.
The EP Publication No. 0 552 657 A1 disclose that pure boswellic acid, physiologically acceptable salts thereof, derivatives thereof and salts of the derivatives or a boswellic acid-containing vegetable preparation may combat inflammatory processes caused by an increased leukotriene formation. Therefore, said publications propose that the compounds be used in particular for treating inflammatory arthropathies, epidermal lesions, allergic and chronic asthma, endotoxin shock, inflammatory bowel diseases and chronic hepatitis and also discloses the use of boswellic acid for treating the inflammatory processes alone or in combination with the other herbal medicines.
Amrita sharma et al., Drug Delivery, 2010, Volume 17(8), pp 587-595 discloses the use of phosphatidyl choline as complexation agent as a strategy for absorption enhancement of boswellic acid.
The US patent No. 7,282,224 B1 discloses the topical pain relief composition comprising capsaicin, a capsaicinoid, a capsaicin analogue and combinations as pain relieving component and Boswellia as inflammation control component.
The US patent No. 7,758,903 B2 discloses composition which comprise at least one ingredient chosen from rosehips, blueberry, blackberry, elderberry, cranberry, rosemary, clove, feverfew, nettle root, artichoke, reishi mushroom, olive extract, green tea extract (epigallocatechin gallate), grape seed extract, resveratrol, viniferin, Aframomum melegueta, boswellia serrata extract, boswellia forte, ipriflavone, tocotrienols, evening primrose oil, INM-176, borage oil, krill oil, at least one type of xanthophyll (e.g., astaxanthin), green coffee extract (chlorogenic acid), and ferulic acid. The PCT publication No. WO 2008/036932A2 relates to compositions and methods for making compositions derived from Boswellia species (frankincense or olibanum) having uniquely elevated volatile oil, boswellic acids, and polysaccharide compounds, particularly, human oral delivery formulations, and methods for use of such compositions, useful e.g. for treating/preventing arthritis, inflammatory disorders, osteoarthritis, rheumatoid diseases and low back pain.
The US publication No. US 2011/0052738 A1 discloses the Boswellia serrata extract and capsaicin in topical pain composition comprising one or more skin penetrants includes soya lecithin, phosphatidyl choline, propylene glycol, derivatized propylene glycol, diethylene glycol monomethylether, diethylene glycol monoethyl ether, propylene glycol monolaurate, tri-block polyethers, isopropyl myristate, stearic acid, dimethyl sulfoxide, poloxamer 407, and combinations thereof. Jan Husch et ah, Fitoterapia, 2013, volume 84, pages 89-98 discloses the enhancement of use of lecithin delivery in the Phytosome® form of Boswellia extract.
The US publication No. 2014/0134261 A1 discloses pharmaceutical composition comprising ester of capsaicin or its analogue and other agent selected from salicylate, menthol, a boswellic acid, DMSO, methyl sulfonylmethane, an NSAID, a corticosteroid, emu oil, an opioid agonist, an opiod antagonist, an NMDA antagonist, tramadol, an a2d ligand, santalol, santalyl acetate, amyris alcohol, amyris acetate, aloe vera gel and aloe vera juice. Pallavi et al., International Journal for Pharmaceutical Research Scholars
(IJPRS), 2014, V-3, 1-3, pages 242-250 discloses the formulation and evaluation of Herbal Gel of Boswellia Serrata for the Management of Gout and the formulation comprising B. serrata extract, Methyl salicylate, Menthol, Aerosil, BHA, BHT and Sesame oil. Inventi Impact NDDS Vol. 2015, Issue 4, 202-2012 discloses pharmaceutical Transdermal Drug Delivery System for Arthritis using Boswellic Acid, PMC E6, oleic acid, HPMC E5, Ethylcellulose, PVP K30, PVA, Tween 20, Oleic acid, PEG 400, Glycerol, DMSO, Methanol and chloroform.
The PCT publication No. WO 2018/020512 A1 discloses the composition for slow/sustained/controlled release of at last one active ingredient wherein the active ingredients are selected from natural phytochemicals, phytochemical is selected from all hydrophobic and hydrophilic natural compounds, but not limited to, Lutein, Caffeine, Resveratrol, Berberin, 95% Curcuminoids, Gingerols, Bacosides, Boswellic Acids, Chlorogenic Acids combinations thereof.
All the prior art references related to the use of Boswellia extract in different compositions and process for the preparations of Boswellia extract. Various dosage forms of Boswellia extract available in the market for treating different conditions or diseases. However, topical gel compositions are not available containing boswellia extract, green coffee bean extract as active ingredients, optionally capsaicin as additional active ingredient and phospholipid as skin penetration enhancer and pharmaceutically acceptable excipients or carriers. The inventors of present invention also provides process for the preparation of topical gel composition comprising steps of dissolving, mixing, sonicating and packing.
OBJECTIVE OF INVENTION
The main objective of the present invention is to provide topical herbal composition comprising natural herbal extracts as active ingredients and pharmaceutically acceptable excipients or carriers.
Another objective of the present invention is to provide topical herbal gel composition comprising boswellia extract and green coffee bean extract as natural herbal extracts, optionally capsaicin as additional active ingredient, phospholipid as skin penetration enhancer and other pharmaceutically acceptable excipients or carriers.
Still another objective of the present invention is to provide process for the preparation of topical herbal gel composition comprising steps of dissolving, mixing, sonicating and packing.
Yet another objective of the present invention is to provide relief of pain in arthritis conditions or relief of musculoskeletal pain by topical application of herbal gel composition of boswellia extract, green coffee bean extract and optionally capsaicin as additional active ingredient and other pharmaceutically acceptable excipients or carriers.
SUMMARY OF INVENTION
One embodiment of the present invention provides topical composition comprising natural herbal extracts as active ingredients and pharmaceutically acceptable excipients or carriers.
Another embodiment of the present invention provides a topical herbal gel composition comprising boswellia extract, green coffee bean extract as natural herbal extracts and optionally, capsaicin as additional active ingredient and pharmaceutically acceptable excipients or carriers.
Another embodiment of the present invention provides a topical herbal gel composition comprising boswellia extract, green coffee bean extract as natural herbal extracts, and optionally, capsaicin as additional active ingredient, phospholipid as skin penetration enhancer and pharmaceutically acceptable excipients or carriers.
Another embodiment of the present invention provides topical herbal gel composition comprising boswellia extract, green coffee bean extract as natural herbal extracts and optionally, capsaicin as additional active ingredient and phospholipid as skin penetration enhancer, solvents, humectants, surfactants, additional penetration enhancer, anti-foaming agents and other pharmaceutically acceptable excipients.
Another embodiment of the present invention provides a topical herbal gel composition comprising boswellia extract, green coffee bean extract as natural herbal extracts and optionally, capsaicin as additional active ingredient and phospholipid as skin penetration enhancer, solvents, humectants, surfactants, additional penetration enhancer, anti-foaming agents and other pharmaceutically acceptable excipients for relief of pain in arthritis condition or for relief of musculoskeletal pain.
In yet another embodiment, the present invention provides a topical herbal gel composition comprising:
0.1% to 10% (w/w) of one or more natural herbal extracts as active ingredients, 0.01% to 0.1% (w/w) of optionally additional active ingredient,
0.1% to 10% (w/w) of penetration enhancer,
1% to 10 % (w/w) of additional penetration enhancer,
1% to 15% (w/w) of humectant,
10% to 70 % (w/w) of surfactant,
0.5% to 20 % (w/w) of solvent,
0.01% to 0.1% (w/w) of anti-foaming agent, and
0.1% to 20% of other pharmaceutically acceptable excipients.
In yet another embodiment, the present invention provides a topical herbal gel composition comprising:
0.1% to 10% (w/w) of one or more natural herbal extracts as active ingredients, 0.01% to 0.1% (w/w) of optionally additional active ingredient,
0.1% to 10% (w/w) of phospholipid as penetration enhancer,
1% to 10 % (w/w) of additional penetration enhancer,
1% to 15% (w/w) of humectant, 10% to 70% (w/w) of surfactant,
0.5% to 20 % (w/w) of solvent,
0.01% to 0.1% (w/w) of anti-foaming agent, and
0.1% to 20% of other pharmaceutically acceptable excipients.
In yet another embodiment, the present invention provides a topical herbal gel composition comprising:
0.1% to 0.5% (w/w) of boswellia extract,
0.1% to 1% (w/w) of green coffee bean extract,
0.01% to 0.1% (w/w) of capsaicin optionally,
0.1 to 10% (w/w) of phosphotidyl choline,
1 to 10 % (w/w) of isopropyl myristate,
10 to 70 % (w/w) of polyethylene glycol 1500,
0.5 to 20 % (w/w) of ethyl alcohol,
0.01% to 0.1% (w/w) of simethicone, and
0.1 to 20% of other pharmaceutically acceptable excipients.
In yet another embodiment of the present invention is to provide process for the preparation of topical herbal gel composition comprising boswellia extract, green coffee bean extract as natural herbal extracts and optionally, capsaicin as additional active ingredient, phospholipid as skin penetration enhancer, solvents, humectants, surfactants, additional penetration enhancer, anti-foaming agents and other pharmaceutically acceptable excipients comprising steps of dissolving, mixing, sonicating and packing.
In yet another embodiment of the present invention provides a process for preparing topical herbal gel composition comprising steps of:
a. adding the natural herbal extracts, optionally additional active ingredient and phospholipid, additional penetration enhancer, surfactant, solvent, humectant, and anti-foaming agent, b. mixing the above mixture by sonication process using Hiescher Ultra sound sonicator for ninety seconds at a time and resting for thirty seconds alternatively till a total power of 50,000 watts energy is used to obtain clear gel preparation.
In yet another embodiment of the present invention provides a process for preparing gel composition of Boswellia extract, coffee bean extract and optionally capsaicin the process comprising steps of :
a. adding the boswellia extract and green coffee bean extract and optionally capsaicin, phosphotidylcholine and polyethylene glycol 1500, glycerine, ethyl alcohol, isopropyl myristate and simethicone,
b. mixing the above mixture by sonication process using Hiescher Ultra sound sonicator for ninety seconds at a time and resting for thirty seconds alternatively till a total power of 50,000 watts energy is used to obtain clear gel preparation.
DETAILED DESCRIPTION OF THE INVENTION
The term "comprising", which is synonymous with "including", "containing", or "characterized by" here in defined as being inclusive or open-ended, and does not exclude additional, unrecited elements or method steps, unless the context clearly requires otherwise.
The present invention was aimed to develop topical herbal gel preparation comprising natural herbal extracts as active ingredients and pharmaceutically acceptable excipients or carriers.
The present invention is to provide topical herbal gel composition comprising boswellia extract, green coffee bean extract as natural herbal extracts and optionally capsaicin as additional active ingredient, phospholipid as skin penetration enhancer and pharmaceutically acceptable excipients or carriers. The present invention is to provide topical herbal gel composition comprising boswellia extract, green coffee bean extract as natural herbal extracts and optionally capsaicin as additional active ingredient, phospholipid as skin penetration enhancer and other pharmaceutically acceptable excipients for relief of pain in arthritis condition or for relief of musculoskeletal pain.
The present invention is to provide an efficient process for the preparation of topical herbal gel composition comprising the steps of dissolving, mixing, sonicating and packing.
The term“active ingredients” of the present invention are used to relieve from pain conditions. Preferably used active ingredients are boswellia extract, green coffee bean extract and optionally, capsaicin as additional active ingredient. Boswellia serrata plant contains boswellic acid as its major active constituent which is present as a- boswellic acid; b- boswellic acid; 3 - acetyl- 11-keto b -boswellic acid (AKBA), responsible for anti- arthritic activity.
The resinous part of Boswellia serrata possesses monoterpenes, diterpenes, triterpenes, tetracyclic triterpenic acids and four major pentacyclic triterpenic acids i.e. b-boswellic acid, acetyl^-boswellic acid, l l-keto^-boswellic acid and acetyl- 11- keto^-boswellic acid, responsible for inhibition of pro-inflammatory enzymes. Out of these four boswellic acids, acetyl- l l-keto^-boswellic acid is the most potent inhibitor of 5-lipoxygenase, an enzyme responsible for inflammation.
Boswellia serrata has been used for a variety of therapeutic purposes such as cancer, analgesia, asthma, inflammation, arthritis, colitis, Crohn’s diseases and hyperlipidemia. Green coffee bean extract Green (or raw) coffee is a major source of CGA in nature (5-12 g/100 g). Chlorogenic acids (CGA) are cinnamic acid derivatives with biological effects mostly related to their antioxidant and anti-inflammatory activities. Chlorogenic acids (CGA) are phenolic compounds formed by the esterification of cinnamic acids, such as caffeic, ferulic, and p-coumaric acids, with (-)-quinic acid.
Capsaicin
Capsaicin and several related compounds are called capsaicinoids and are produced as secondary metabolites by chili peppers, probably as deterrents against certain mammals and fungi. Pure capsaicin is a hydrophobic, colorless, highly pungent, and crystalline to waxy solid compound.
Capsaicin is used as an analgesic in topical ointments and dermal patches to relieve pain, typically in concentrations between 0.025% and 0.1%. It may be applied in cream form for the temporary relief of minor aches and pains of muscles and joints associated with arthritis, backache, strains and sprains, often in compounds with other rubefacients. Capsaicin exhibits anti-inflammatory property by inhibiting IkB-a degradation in LPS- stimulated peritoneal macrophages and it has both analgesic and anti-inflammatory properties.
It is also used to reduce the symptoms of peripheral neuropathy, such as post herpetic neuralgia caused by shingles. Capsaicin transdermal patch (Qutenza) for the management of this particular therapeutic indication (pain due to post-herpetic neuralgia) was approved as a therapeutic by the U.S. FDA. One of clinical studies having limited quality found that high-dose topical capsaicin (8%) compared with control (0.4% capsaicin) provided moderate to substantial pain relief from post herpetic neuralgia, HIV-neuropathy, and diabetic neuropathy. Phosphatidylcholines are a class of phospholipids that incorporate choline as a head group. They are a major component of biological membranes and can be easily obtained from a variety of readily available sources, such as egg yolk or soybeans, from which they are mechanically or chemically extracted using hexane.
Phosphatidylcholine is a chemical contained in eggs, soybeans, mustard, sunflower, and other foods. It is found naturally in the body in all cells. The term "phosphatidylcholine" is sometimes used interchangeably with "lecithin," although the two are different.
Phosphatidylcholine is a major constituent of cell membranes and pulmonary surfactant, and is more commonly found in the exoplasmic or outer leaflet of a cell membrane. It is thought to be transported between membranes within the cell by phosphatidylcholine transfer protein (PCTP). Phosphatidylcholine also plays a role in membrane-mediated cell signaling and PCTP activation of other enzymes.
One or more skin penetration enhancers selected from the group consisting of soya lecithin, phosphatidyl choline, propylene glycol, derivatized propylene glycol, diethylene glycol monomethylether, diethylene glycol monoethyl ether, propylene glycol monolaurate, tri-block polyethers, isopropyl myristate, stearic acid, dimethyl sulfoxide, poloxamer 407, and combinations thereof. Preferably, skin penetration enhancer is phosphatidyl choline and Preferably, isopropyl myristate is additional skin penetration enhancer.
Penetration enhancer used in the herbal gel composition is in the range of 0.1 to 10 %(w/w), more preferably in the range of 1% to 5% (w/w) of the total weight of the composition. Additional penetration enhancer used in the herbal gel composition is in the range of 1% to 10 % (w/w) of additional penetration enhancer, more preferably in the range of 1% to 5% (w/w) of the total weight of the composition. In an embodiment, the solvent is selected from a group comprising ethyl alcohol, isopropyl alcohol, glycofurol, polyethylene glycol (PEG 200, 400), glycerol, polypropylene glycol, propylene glycol, N-methyl-2-pyrolidone and ethyl alcohol or mixture thereof. Preferably, the solvent is ethyl alcohol.
Solvent used in the herbal gel composition is in the range of 0.5% to 20% (w/w), more preferably in the range of 5% to 15% (w/w) of the total weight of the composition. In an embodiment, the preferred surfactant referred above can be polyglutamic acid, Polyethylene glycol, propylene glycol, glycerol, propylene glycol esters, polyglycerol oleate polyvinyl alcohol, non-ethoxylated polymers like Glyceryl Stearate (and) Polyglyceryl-6 Palmitate/Succinate (and) Cetearyl Alcohol and N-(2- Hydroxypropyl) methacrylamide (PHPMA). Preferred polyethylene glycols having a molecular weight range from about 300 to about 1500. More preferred are the polyethylene glycols having a molecular weight range from about 600 to about 1500. Most preferred are the polyethylene glycols having a high molecular weight range from about 1500.
Surfactant used in the herbal gel composition is in the range of 10% to 70% (w/w), more preferably in the range of 30% to 64.5% (w/w) of the total weight of the composition.
Humectants include but are not limited to glycerine, sorbitol, propylene glycol, Butylene Glycol, Aluminum Hydroxide Adjuvant, Ammonium Alginate, Cyclomethicone, Polydextrose, Sodium Hyaluronate, Sodium Lactate, Triacetin, Triethanolamine and Xylitol. Preferably, the humectant is glycerine.
Humectants used in the herbal gel composition is in the range of 1% to 15% (w/w), more preferably in the range of 5% to 10% (w/w) of the total weight of the composition.
Anti-foam agents and defoamer are often used interchangeably and commonly used in the compositions of the present invention are Simethicone, polydimethylsiloxanes and other silicones, certain alcohols, stearates and glycols, Alkyl poly acrylates, Castor oil, Fatty acids, Fatty acids esters, Fatty acids sulfate, Fatty alcohol, Fatty alcohol esters, Fatty alcohol sulfate, Foot olive oil, Mono & Di Glyceride, Paraffin oil, Paraffin Wax, Poly Propylene Glycol, Silicones Oil, Vegetable & animal fats. More preferably Simethicone is used.
Anti-foam agent and defoamer used in the herbal gel composition is in the range of 0.01 to 0.1% (w/w), more preferably in the range of 0.05 to 0.1% (w/w) of the total weight of the composition.
Other excipients or carriers used in the preparations to the compositions of this invention, the following can be used and there were no limitations: stabilizer, plasticizer, lubricant, reducing agent, buffer agent, base, adsorbent, corrigent, binder, suspending agent, antioxidant, wetting agent, wet modifier, filler, refrigerative agent, coloring matter, flavoring agent, perfume, isotonizing agent, softener, emulsifying agent, foaming agent, pH modifier, anti-frothing agents, flavouring agents, preservatives, dispersing agent, fragrance, desiccant, antiseptics, preservative, solubilizing agent, solubilizer, solvent, superplasticizer, antistatic agent, extender, moisturizing agent and the like.
Manufacturing process for topical herbal gel composition: a. adding the natural herbal extracts, optionally additional active ingredient and phospholipid as skin penetration enhancer, additional penetration enhancer, surfactant, solvent, humectant, and anti-foaming agent, b. mixing the above mixture by sonication process using Hiescher Ultra sound sonicator for ninety seconds at a time and resting for thirty seconds alternatively till a total power of 50,000 watts energy is used to obtain clear gel preparation.
The following examples describes the nature of the invention and are given only for the purpose of illustrating the present invention in more detail and are not limitative and relate to solutions, which have been particularly effective on bench scale.
Example 1
Figure imgf000019_0001
Example 2
Figure imgf000019_0002
Figure imgf000020_0001
Example 3
Figure imgf000020_0002
Example 4
Figure imgf000020_0003
Figure imgf000021_0001
Manufacturing process: a. adding the boswellia extract, green coffee bean extract and optionally capsaicin as additional active ingredient and phosphotidyl choline and polyethylene glycol 1500, glycerine, ethyl alcohol, isopropyl myristate and simethicone, b. mixing the above mixture by sonication process using Hiescher Ultra sound sonicator for ninety seconds at a time and resting for thirty seconds alternatively till a total power of 50,000 watts energy is used to obtain clear gel preparation.

Claims

We Claim:
1. A topical herbal gel composition comprising boswellia extract, green coffee bean extract as natural herbal extracts pharmaceutically acceptable excipients or carriers.
2. The topical herbal gel composition as claimed in claim 1, optionally contains capsaicin as additional active ingredient.
3. The topical herbal gel composition as claimed in claims 1 and 2, contain phospholipid as skin penetration enhancer.
4. The topical herbal gel composition as claimed in claims 1 to 3, further contain solvents, humectants, surfactants, additional penetration enhancer, anti-foaming agents and other pharmaceutically acceptable excipients.
5. The topical herbal gel composition as claimed in claim 3, wherein skin penetration enhancer is selected from the group consisting of soya lecithin, phosphatidyl choline, propylene glycol, derivatized propylene glycol, diethylene glycol monomethylether, diethylene glycol monoethyl ether, propylene glycol monolaurate, tri-block polyethers, isopropyl myristate, stearic acid, dimethyl sulfoxide, poloxamer 407 or combinations thereof.
6. The topical herbal gel composition as claimed in claim 4, wherein the additional skin penetration enhancer is selected from the group consisting of soya lecithin, phosphatidyl choline, propylene glycol, derivatized propylene glycol, diethylene glycol monomethylether, diethylene glycol monoethyl ether, propylene glycol monolaurate, tri-block polyethers, isopropyl myristate, stearic acid, dimethyl sulfoxide, poloxamer 407 or combinations thereof.
7. The topical herbal gel composition as claimed in claim 4, wherein the solvent is selected from a group comprising ethyl alcohol, isopropyl alcohol, glycofurol, polyethylene glycol (PEG 200, 400), glycerol, polypropylene glycol, propylene glycol, N-methyl-2-pyrolidone and ethyl alcohol or mixture thereof.
8. The topical herbal gel composition as claimed in claim 4, wherein the surfactant is selected from a group comprising polyglutamic acid, Polyethylene glycol, propylene glycol, glycerol, propylene glycol esters, polyglycerol oleate polyvinyl alcohol, non-ethoxylated polymers like Glyceryl Stearate (and) Polyglyceryl-6 Palmitate/Succinate (and) cetearyl alcohol and N-(2- hydroxypropyl) methacrylamide (PHPMA), preferred polyethylene glycols having a molecular weight range from about 300 to about 1500.
9. The topical herbal gel composition as claimed in claim 4, wherein the humectants is selected from glycerine, sorbitol, propylene glycol, butylene glycol, aluminum hydroxide adjuvant, ammonium alginate, cyclomethicone, polydextrose, sodium hyaluronate, sodium lactate, triacetin, triethanolamine and xylitol.
10. The topical herbal gel composition as claimed in claim 4, wherein the anti-foam agent and defoamer is selected from simethicone, polydimethylsiloxanes and other silicones, certain alcohols, stearates and glycols, alkyl poly acrylates, castor oil, fatty acids, fatty acids esters, fatty acids sulfate, fatty alcohol, fatty alcohol esters, fatty alcohol sulfate, foot olive oil, mono & di glyceride, paraffin oil, paraffin wax, poly propylene glycol, silicones oil, vegetable and animal fats.
11. The topical herbal gel composition as claimed in claim 4, wherein the other pharmaceutically acceptable excipients or carriers, are selected from stabilizer, plasticizer, lubricant, reducing agent, buffer agent, base, adsorbent, corrigent, binder, suspending agent, antioxidant, wetting agent, wet modifier, filler, refrigerative agent, coloring matter, flavoring agent, perfume, isotonizing agent, softener, emulsifying agent, foaming agent, pH modifier, anti-frothing agents, flavouring agents, preservatives, dispersing agent, fragrance, desiccant, antiseptics, preservative, solubilizing agent, solubilizer, solvent, superplasticizer, antistatic agent, extender, moisturizing agent and the like.
12. The topical herbal gel composition as claimed in claims 1 to 11, wherein the composition specifically comprising:
0.1% to 10% (w/w) of one or more natural herbal extracts as active ingredients, 0.01% to 0.1% (w/w) of optionally additional active ingredient,
0.1% to 10% (w/w) of penetration enhancer,
1% to 10 % (w/w) of additional penetration enhancer, 1% to 15% (w/w) of humectant,
10% to 70 % (w/w) of surfactant,
0.5% to 20 % (w/w) of solvent,
0.01% to 0.1% (w/w) of anti-foaming agent, and
0.1% to 20% of other pharmaceutically acceptable excipients.
13. The topical herbal gel composition as claimed in claims 1 to 12 prepared by a process comprising the steps of:
a. adding the natural herbal extracts, optionally additional active ingredient and phospholipid; additional penetration enhancer, surfactant, solvent, humectant, and anti-foaming agent,
b. mixing the above mixture by sonication process using Hiescher Ultra sound sonicator for ninety seconds at a time and resting for thirty seconds alternatively till a total power of 50,000 watts energy is used to obtain clear gel preparation.
PCT/IB2020/054662 2019-04-04 2020-05-17 Herbal gel composition and its process of preparation WO2020202128A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201941013674 2019-04-04
IN201941013674 2019-04-04

Publications (1)

Publication Number Publication Date
WO2020202128A1 true WO2020202128A1 (en) 2020-10-08

Family

ID=72667126

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2020/054662 WO2020202128A1 (en) 2019-04-04 2020-05-17 Herbal gel composition and its process of preparation

Country Status (1)

Country Link
WO (1) WO2020202128A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022155352A1 (en) * 2021-01-13 2022-07-21 Dyve Biosciences, Inc. Transdermal penetrant formulations for administration of medicaments

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7282224B1 (en) * 2006-06-09 2007-10-16 Guthy-Renker Corporation Pain relief composition
US7758902B2 (en) * 2003-09-12 2010-07-20 Access Business Group International Llc Cytokine modulators and related methods of use
WO2019014380A1 (en) * 2017-07-12 2019-01-17 James Blanchard Platforms for topical delivery of medicaments and methods for their preparation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7758902B2 (en) * 2003-09-12 2010-07-20 Access Business Group International Llc Cytokine modulators and related methods of use
US7282224B1 (en) * 2006-06-09 2007-10-16 Guthy-Renker Corporation Pain relief composition
WO2019014380A1 (en) * 2017-07-12 2019-01-17 James Blanchard Platforms for topical delivery of medicaments and methods for their preparation

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE Nuskha-E-Qatoor 18 August 2020 (2020-08-18), Database accession no. AH5/2664 *
DATABASE Sallaki Guna 18 August 2020 (2020-08-18), Database accession no. R S8/696 *
DATABASE Tila E Filfil Surkh 18 August 2020 (2020-08-18), Database accession no. JA6/741Y *
H. KATHPALIA ET AL.: "Topical Nanoemmigel Formulation of Boswellia serrata", INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 80, no. 2, March 2018 (2018-03-01), pages 261 - 267, XP055747048 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022155352A1 (en) * 2021-01-13 2022-07-21 Dyve Biosciences, Inc. Transdermal penetrant formulations for administration of medicaments

Similar Documents

Publication Publication Date Title
Upaganlawar et al. Pharmacological activities of Boswellia serrata Roxb.-mini review
JP2004537575A (en) Nutritional supplements and their use
US20050123560A1 (en) High purity and water dispersible extract and formulations of larrea tridentata leaf resin, and methods of making and using the same
AU2018253410A1 (en) Extracts of Cynara cardunculus and Citrus aurantium bergamia, combinations thereof, and formulations containing them
US11564963B2 (en) Topical compositions, process of large-scale manufacture, and method of use
US11285185B2 (en) Methods for treating in dermatology and dermo-cosmetics by administering Silybum marianum achene extract
AU2022222528A1 (en) Novel arthritis emulgel composition and its preparation process
KR20090103000A (en) Pharmaceutical composition for the treatment of arthritis
WO2020234650A1 (en) Pharmaceutical compositions comprising cbd and terpene compositions
WO2020202128A1 (en) Herbal gel composition and its process of preparation
WO2020146478A1 (en) Cannabinoid formulations for treating alcohol hangover
Ren et al. Traditional uses, phytochemistry, pharmacology and toxicology of rhizoma phragmitis: a narrative review
US20100003351A1 (en) Compositions comprising rhodiola rosea and methods of use thereof
US11903987B2 (en) Artificial compositions comprising corosolic acid, oleanolic acid; and ursolic acid in a form of an emulsion, salve, ointment, suspension, or gel
EP0804929A2 (en) Treatment of schistosomiasis
Paarakh Coriandrum sativum Linn. — Review
EA029402B1 (en) Transdermal agent for treating and preventing joint and soft tissue diseases, combined transdermal preparation for treating and preventing joint and soft tissue diseases and method for production thereof
EP2485718A1 (en) Use of a compound based on eremophilanolides
CN113616801A (en) Preparation method and application of antiseptic and antibacterial preparation containing Scutellariae radix extract
DE202020104968U1 (en) Sprayable composition of a throat spray
KR20210013100A (en) Formulations comprising lipophilic extracts of spicy edible plants, useful for controlling pain and inflammation.
Ubong-Isaac et al. Herbosomes in the delivery of phytotherapeutics and nutraceuticals: concepts, applications and future perspective
EP3871672B1 (en) Comfreyns, arylnaphthalene lignans that inhibit pro-inflammatory gene expression, and pharmaceutical composition comprising them
LU102146B1 (en) Sprayable composition of a throat spray
ITMI20130807A1 (en) COMBINATIONS OF SERENOA REPENS EXTRACTS AND LIPOFILE EXTRACTS BY ZINGIBER OFFICINALIS AND ECHINACEA ANGUSTIFOLIA, THEIR USE AND FORMULATIONS THAT CONTAIN THEM

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20783101

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20783101

Country of ref document: EP

Kind code of ref document: A1